Spike proteins are the hallmark of SARS-Cov-2, which bind to ACE2 receptors that lead to cell and membrane fusion. To address and alleviate respiratory health issues, we at Shiban Pharma have ...

Spike proteins are the hallmark of SARS-Cov-2, which bind to ACE2 receptors that lead to cell and membrane fusion. To address and alleviate respiratory health issues, we at Shiban Pharma have ...

It's been five years since COVID-19 was declared a global pandemic. As SARS-CoV-2 shifts to endemic status, questions about its future evolution remain.

It's been five years since COVID-19 was declared a global pandemic. As SARS-CoV-2 shifts to endemic status, questions about its future evolution remain. New variants of the virus will likely emerge, ...

It's been five years since COVID-19 was declared a global pandemic. As SARS-CoV-2 shifts to endemic status, questions about ...

When the COVID-19 pandemic first began, we saw how quickly the SARS-CoV-2 virus evolved. New variants emerged with mutations that increased transmissibility or helped the virus evade our immune ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

Introduction: A new generation of mucosal vaccine against the ever-evolving SARS-CoV-2 is of great value to fight COVID-19. In previous studies, our groups developed a viral vector vaccine based on an ...

In this study, the adhesion-blocking dispirotripiperazine core compound PDSTP was evaluated against SARS-CoV-2 in vitro and in vivo. We demonstrated that the molecule was acceptably active against two ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...